Entering text into the input field will update the search result below

Dicerna reports updated data for DCR-PHXC in PH1 and PH2

  • Dicerna Pharmaceuticals (DRNA) presents updated data from its ongoing PHYOX 1 Phase 1 trial evaluating DCR-PHXC, a GalXC product candidate.
  • The data showed post-dose reductions in 24-hour urinary oxalate levels in adult and adolescent study participants with primary hyperoxaluria type 1 (PH1) and type 2 (PH2).
  • A single dose led to normalization or near-normalization of urinary oxalate levels in a majority of participants and was generally well-tolerated.
  • DCR-PHXC is an RNAi therapeutic based on the company's GalXC platform which enables subcutaneous administration.

Recommended For You

About NVO Stock

SymbolLast Price% Chg
Market Cap
PE
Yield (TTM)
Rev Growth (YoY)
Prev. Close
Compare to Peers

Related Stocks

SymbolLast Price% Chg
NVO--
Novo Nordisk A/S